Key takeaways from the updated multidisciplinary European MASLD guidelines
Open Access
- 1 April 2025
- journal article
- review article
- Published by BMJ in eGastroenterology
- Vol. 3 (2) , e100196
Abstract
The new European clinical practice guidelines from three scientific societies (European Association for the Study of the Liver, European Association for the Study of Diabetes and European Association for the Study of Obesity) on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) provide detailed recommendations on diagnosis, risk stratification, monitoring strategies, treatment and prevention. Lifestyle interventions (eg, weight reduction, Mediterranean diet, exercise, alcohol abstinence) and the treatment of cardiometabolic risk factors continue to be the mainstay of treatment and prevention of the disease. Incretin mimetics that are approved to treat obesity and/or type 2 diabetes such as semaglutide and tirzepatide have benefits for ameliorating metabolic dysfunction-associated steatohepatitis (MASH). Novel developments include adapted strategies for screening (case finding) using non-invasive tests (NITs) with a focus on detecting fibrosis or cirrhosis, risk-adjusted monitoring of MASLD by NITs as well as the recommendation to use, if locally approved, the thyroid hormone receptor β-agonist resmetirom in patients with non-cirrhotic MASH fibrosis (≥F2 stage).Keywords
This publication has 52 references indexed in Scilit:
- Misclassified Alcohol-related Liver Disease is Common in Presumed Metabolic Dysfunction-associated Steatotic Liver Disease and Highly Increases Risk for Future CirrhosisClinical Gastroenterology and Hepatology, 2024
- Practical guideline on obesity care in patients with gastrointestinal and liver diseases – Joint ESPEN/UEG guidelineClinical Nutrition, 2023
- The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysisClinical Nutrition, 2022
- Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic SteatohepatitisJAMA, 2021
- Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis–Related, Child–Pugh A CirrhosisClinical Gastroenterology and Hepatology, 2021
- Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis StageClinical Gastroenterology and Hepatology, 2019
- Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet studyHepatology, 2017
- Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitisHepatology, 2013
- Association Between Anthropometric Parameters and Measurements of Liver Stiffness by Transient ElastographyClinical Gastroenterology and Hepatology, 2013
- Obesity is an independent risk factor for clinical decompensation in patients with cirrhosisHepatology, 2011